Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra in active psoriatic arthritis
NCT06878404Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of icotrokinra in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Feb 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06878404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878404.